NASDAQ:TPTX Turning Point Therapeutics (TPTX) Stock Price, News & Analysis → SHOCKING Crypto Leak… (From Crypto 101 Media) (Ad) Free TPTX Stock Alerts Notice: This company has been marked as potentially delisted and may not be actively trading. Add Compare Share Share Today's Range$76.01▼$76.0150-Day Range$74.80▼$76.0152-Week Range$23.77▼$82.20Volume4,322 shsAverage Volume1.14 million shsMarket Capitalization$3.81 billionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock Analysis Get Turning Point Therapeutics alerts: Email Address Ad Crypto 101 MediaSHOCKING Crypto Leak…A shocking leak has revealed tech giant Microsoft's plans to add crypto support to future products. If the plans in these leaked internal documents pan out, we could see prices skyrocket for Bitcoin, Ethereum, XRP and MORE… The coupling of gaming and cryptocurrency could absolutely transform digital finance as we know it in 2024. Claim your free seat by clicking here now. About Turning Point Therapeutics Stock (NASDAQ:TPTX)Turning Point Therapeutics, Inc., a clinical-stage precision oncology biopharmaceutical company, engages in designing and developing therapies that target genetic drivers of cancer. It develops a pipeline of tyrosine kinase inhibitors (TKIs) that targets genetic drivers of cancer in TKI-naïve and TKI-pretreated patients. The company's lead drug candidate repotrectinib is being evaluated in an ongoing Phase 1/2 trial called TRIDENT-1 for the treatment of patients with ROS1+ advanced non-small-cell lung cancer (NSCLC) and patients with ROS1+ and NTRK+ advanced solid tumors. It also develops TPX-0022, a MET/SRC/CSF1R inhibitor, which is in Phase 1 SHIELD-1 clinical trial for patients with advanced solid tumors harboring genetic alterations in MET; TPX-0046, a RET inhibitor that is in 1/2 SWORD-1 clinical trial for patients with advanced solid tumors harboring RET genetic alterations; and TPX-0131, an ALK inhibitor, which is in Phase 1/2 FORGE-1 study for patient with advanced or metastatic TKI-pretreated ALK-positive NSCLC. Turning Point Therapeutics, Inc. was founded in 2013 and is headquartered in San Diego, California.Read More Ad Crypto 101 MediaSHOCKING Crypto Leak…A shocking leak has revealed tech giant Microsoft's plans to add crypto support to future products. If the plans in these leaked internal documents pan out, we could see prices skyrocket for Bitcoin, Ethereum, XRP and MORE… The coupling of gaming and cryptocurrency could absolutely transform digital finance as we know it in 2024. Claim your free seat by clicking here now. TPTX Stock News HeadlinesFebruary 17, 2024 | wsj.comTurning Point Brands Inc.February 12, 2024 | bbc.co.ukAlzheimer’s: A Turning Point?April 24, 2024 | Crypto 101 Media (Ad)SHOCKING Crypto Leak…A shocking leak has revealed tech giant Microsoft's plans to add crypto support to future products. If the plans in these leaked internal documents pan out, we could see prices skyrocket for Bitcoin, Ethereum, XRP and MORE… The coupling of gaming and cryptocurrency could absolutely transform digital finance as we know it in 2024. February 10, 2024 | investing.comTurning Point Brands Inc (TPB)February 10, 2024 | benzinga.comCormorant Asset Management, LP's Net WorthJanuary 15, 2024 | bbc.co.ukSolving quadratic equations - EdexcelDecember 19, 2023 | morningstar.comCOP15: A Turning Point for Investor Approaches to BiodiversityDecember 16, 2023 | bbc.comTurning Point USA: Are conservatives fighting back on campus?April 24, 2024 | Crypto 101 Media (Ad)SHOCKING Crypto Leak…A shocking leak has revealed tech giant Microsoft's plans to add crypto support to future products. If the plans in these leaked internal documents pan out, we could see prices skyrocket for Bitcoin, Ethereum, XRP and MORE… The coupling of gaming and cryptocurrency could absolutely transform digital finance as we know it in 2024. July 29, 2023 | ft.comTattoos have reached a turning point at workJuly 11, 2023 | newsweek.comTurning Point USAJune 23, 2023 | health.usnews.comTurning Point HospitalJune 5, 2023 | bbc.co.ukCan Vinicius episode be a turning point in football’s racism battle?May 24, 2023 | usnews.comTurning Point Secondary SchoolApril 12, 2023 | ca.finance.yahoo.com2023 could be turning point for office-to-housing conversions: ColliersMarch 22, 2023 | theguardian.comThe invasion of Iraq was a turning point on to a path that led towards UkraineMarch 22, 2023 | news.yahoo.comPutin's arrest warrant is turning point – ZelenskyyMarch 22, 2023 | foxnews.comZelenskyy: Putin's arrest warrant marks 'turning point,' he’ll be held responsible for 'every destroyed life'March 21, 2023 | news.yahoo.com2023 may be turning point in impact of sanctions on RussiaMarch 21, 2023 | uk.news.yahoo.com'Deposit return scheme can be turning point in litter battle'March 19, 2023 | benzinga.comTurning Point Ministries Welcomes New Chief Development OfficerMarch 14, 2023 | stocknews.com1 Stock to Buy This Week and Hold for the Next 20 YearsMarch 8, 2023 | mirror.co.ukHarry and Meghan's 'whining' Netflix series was 'turning point' with US, says authorMarch 1, 2023 | ft.comWhy 2023 might just be a turning point for climate actionFebruary 26, 2023 | mirror.co.ukBruno Fernandes outlines Man Utd turning point after "really bad" momentFebruary 25, 2023 | seekingalpha.comTurning Point Brands raises dividend by 8% to $0.065February 19, 2023 | msn.comThese 4 major new Indian military inductions mark a positive turning pointSee More Headlines Receive TPTX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Turning Point Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings11/09/2021Today4/23/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical Preparations Sub-IndustryN/A Current SymbolNASDAQ:TPTX CUSIPN/A CIK1595893 Webwww.tptherapeutics.com Phone(858) 926-5251FaxN/AEmployees250Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)($6.90) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-236,550,000.00 Net MarginsN/A Pretax Margin-33,959.03% Return on Equity-37.45% Return on Assets-35.62% Debt Debt-to-Equity RatioN/A Current Ratio16.83 Quick Ratio16.83 Sales & Book Value Annual Sales$30.83 million Price / Sales123.46 Cash FlowN/A Price / Cash FlowN/A Book Value$15.84 per share Price / Book4.80Miscellaneous Outstanding Shares50,074,000Free Float45,768,000Market Cap$3.81 billion OptionableNot Optionable Beta-0.18 12 Stocks Corporate Insiders are AbandoningIf a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know?Get This Free Report Key ExecutivesDr. Athena Maria Countouriotis M.D. (Age 50)Pres, CEO & Director Comp: $1.19MMr. Paolo Tombesi (Age 58)Exec. VP & CFO Comp: $741.19kDr. Mohammad Hirmand (Age 52)Exec. VP & Chief Medical Officer Comp: $783.77kMr. Ed GemoSr. VP & Chief Information OfficerDr. Gavin Hirst Ph.D.Sr. VP of Chemistry & Interim Chief Scientific OfficerDr. Adam D. Levy M.B.A.Ph.D., Sr. VP of Investor Relations & Corp. CommunicationsMr. Raymond J. Furey J.D. (Age 54)Sr. VP & Chief Compliance Officer Mr. Brian Sun J.D. (Age 38)M.S., Sr. VP, Gen. Counsel & Corp. Sec. Ms. Heather AdamsSr. VP of HRDr. Jeffrey P. WhittenSr. VP of Pre-Clinical Devel.More ExecutivesKey CompetitorsCymaBay TherapeuticsNASDAQ:CBAYUltragenyx PharmaceuticalNASDAQ:RAREInsmedNASDAQ:INSMPrestige Consumer HealthcareNYSE:PBHAlkermesNASDAQ:ALKSView All Competitors TPTX Stock Analysis - Frequently Asked Questions How were Turning Point Therapeutics' earnings last quarter? Turning Point Therapeutics, Inc. (NASDAQ:TPTX) announced its quarterly earnings results on Tuesday, November, 9th. The company reported ($1.34) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.26) by $0.08. The company earned $0.46 million during the quarter. During the same period in the prior year, the business posted ($0.42) EPS. What other stocks do shareholders of Turning Point Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Turning Point Therapeutics investors own include NVIDIA (NVDA), Main Street Capital (MAIN), OPKO Health (OPK), Boeing (BA), General Motors (GM), AbbVie (ABBV), Gilead Sciences (GILD), GSK (GSK), Johnson & Johnson (JNJ) and Livongo Health (LVGO). When did Turning Point Therapeutics IPO? Turning Point Therapeutics (TPTX) raised $167 million in an initial public offering (IPO) on Wednesday, April 17th 2019. The company issued 9,300,000 shares at a price of $18.00 per share. Goldman Sachs, SVB Leerink and Wells Fargo Securities served as the underwriters for the IPO and Canaccord Genuity was co-manager. This page (NASDAQ:TPTX) was last updated on 4/24/2024 by MarketBeat.com Staff From Our PartnersSHOCKING Crypto Leak…Crypto 101 Mediatop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)Traders AgencyDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsDon’t Miss Out on the AI Gold Rush That’s Just Getting StartedBanyan Hill PublishingMan Who Predicted 2008: “This Will be Worse.”AltimetryBiden out June 13; Kamala won’t replace him?Paradigm PressTiny Biotech Stock Wins $75 Billion PatentBehind the MarketsFed launches fourth dollar overhaulStansberry Research Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Turning Point Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
